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Abstract
Background: Neuroblastoma is the most common, pediatric, extra-cranial, malignant solid tumor. Despite
multimodal therapeutic protocols, outcome for children with a high-risk clinical phenotype remains poor, with
long-term survival still less than 40%. Hereby, we evaluated the potential of non-coding RNA expression to
predict outcome in high-risk, stage 4 neuroblastoma.
Methods: We analyzed expression of 481 Ultra Conserved Regions (UCRs) by reverse transcription-quantitative
real-time PCR and of 723 microRNAs by microarrays in 34 high-risk, stage 4 neuroblastoma patients.
Results: First, the comparison of 8 short- versus 12 long-term survivors showed that 54 UCRs were significantly
(P < 0.0491) over-expressed in the former group. For 48 Ultra Conserved Region (UCRs) the expression levels
above the cut-off values defined by ROC curves were strongly associated with good-outcome (OS: 0.0001 <P <
0.0185, EFS: 0.0001 <P < 0.0491). Then we tested the Transcribed-UCR (T-UCR) threshold risk-prediction model
on an independent cohort of 14 patients. The expression profile of 28 T-UCRs was significantly associated to
prognosis and at least 15 up-regulated T-UCRs are needed to discriminate (P < 0.0001) short- from long-survivors
at the highest sensitivity and specificity (94.12%). We also identified a signature of 13 microRNAs differently
expressed between long- and short-surviving patients. The comparative analysis of the two classes of non-coding
RNAs disclosed that 9 T-UCRs display their expression level that are inversely correlated with expression of 5
complementary microRNAs of the signature, indicating a negative regulation of T-UCRs by direct interaction with
microRNAs. Moreover, 4 microRNAs down-regulated in tumors of long-survivors target 3 genes implicated in
neuronal differentiation, that are known to be over-expressed in low-risk tumors.
Conclusions: Our pilot study suggests that a deregulation of the microRNA/T-UCR network may play an
important role in the pathogenesis of neuroblastoma. After further validation on a larger independent set of
samples, such findings may be applied as the first T-UCR prognostic signature for high-risk neuroblastoma
patients.
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Background
Neuroblastoma (NB) is a pediatric tumor of the sympa-
thetic nervous system characterized by a remarkable het-
erogeneous clinical behavior [1]. Patients with localized
NB have a favorable outcome, and in infants with dissem-
inated stage 4 tumor the progression of disease is gener-
ally halted by good response to therapy. Conversely, only
20-30% of children older than 12 months of age - or 18
months, according to a more recent classification [2] -
with a stage 4 tumor show progression free- and overall-
survival longer than 60 months, despite multimodal ther-
apeutic protocols [3]. In recent years several prognostic
signatures derived from gene expression profiles, DNA
abnormalities, and microRNAs [4-9] have been proposed
as sensitive indicators of tumor progression in NB
patients. Yet, the major challenges remain to validate each
gene classifier on independent patient cohorts, and to
identify additional tumor-specific prognostic markers for
improved risk estimation at the time of diagnosis, espe-
cially in high-risk NB patients.
Recently, Calin et al. [10] have demonstrated that a newly
discovered class of Ultra Conserved Regions (UCRs) [11]
is significantly altered at both DNA and RNA levels in
adult chronic lymphocytic leukemias, colorectal and
hepatocellular carcinomas. Moreover, they found that
tumor-associated Transcribed-UCRs (T-UCRs) in leuke-
mias are regulated by microRNAs, leading to the hypoth-
esis that both coding and noncoding RNAs may define
signatures associated with diagnosis, prognosis, and
response to treatment. So far, there are no reports about
the expression of T-UCRs in NB and there is presently only
one published study on microRNA deregulation and NB
prognosis [9]. Here we profiled both T-UCRs and microR-
NAs in a cohort of 34 high-risk NBs, with the aim to inves-
tigate their putative role as sensitive markers of outcome
prediction in children with stage 4 NB, a major challenge
to clinicians and researchers. Our pilot study suggests for
the first time that a signature based on T-UCR expression
is associated with good outcome in non infant patients
diagnosed with metastatic NB, and lets us assume putative
complex regulatory interplays between T-UCRs and
microRNAs in neuroblastoma. The potential to use this
information must be tested in a larger, independent set of
samples.
Methods
Tumor samples
Tumor specimens were collected at the onset of disease
from 34 patients who were diagnosed with a primary NB
between 1990 and 2006, and referred to the Gaslini Chil-
dren Hospital, Genoa, Italy. The study was approved by
Ethics committee of the Gaslini Children Hospital, and
informed consent was obtained by all children's legal
guardians. All patients were classified as stage 4 according
to the International Neuroblastoma Staging System [12],
and they were older than 1 year of age at time of diagnosis
(average age: 39.2 months). Regarding the clinical course,
patients were categorized into two subgroups: "short-sur-
vivors" (dead of disease within 36 months from diagno-
sis. Deaths due to toxicity were censored) and "long-
survivors" (alive with an overall survival time > 36
months). Long- and short-surviving patients did not differ
by year of diagnosis. Patient and tumor characteristics are
summarized in additional file 1: Table S1.
The study was initially conducted on a cohort of 20
patients: 8 short-survivors (median follow-up time: 18
months, range 6-34 months; median event-free surviving
time: 14 months, range 5-29 months) and 12 long-survi-
vors (median follow-up time: 86 months, range 39-164
months; median event-free surviving time: 72 months,
range 22-164 months). None but 2 long-surviving
patients (#1558 and #2056) had relapse or progression of
disease. Case #1558 had a local relapse after 22 months
from diagnosis and is in complete remission with a fol-
low-up time of 112 months. Patient #2056 had a progres-
sion of disease after 70 months from diagnosis and at the
time of analysis is alive with stable disease (follow-up
time: 76 months).
Then, the T-UCR threshold risk-prediction model
obtained from this group of patients was tested in an inde-
pendent cohort of 14 patients. Within this set, 9 patients
were included in the short-survivor group (median fol-
low-up time: 18 months, range 1-35 months; event-free
surviving time: 13 months, range 1-22 months) and 5 in
the long-survivor one (median follow-up time: 53
months, range 40-67 months). The latter group of
patients had neither relapse nor progression of disease.
All tumor samples were classified as Schwannian stroma-
poor neuroblastoma according to the International Neu-
roblastoma Pathology Committee [13], with at least 80%
of neuroblasts. Amplification of the MYCN oncogene was
present in tumors of 5 short- and 2 long-surviving
patients.
Reverse transcription quantitative real-time PCR (RT-
qPCR)
Total RNA was extracted from frozen tumors by Perfect-
Pure™ RNA Tissue Kit (5Prime, Hamburg, Germany),
including RNase-free DNase I treatment. Total and small
RNAs were quantified and quality control was assessed by
RNA 6000 Nano® and Small RNA® assays, respectively, on
the 2100 Bioanalyzer (Agilent Technologies, Santa Clara,
CA). Only samples with RNA integrity number ≥ 6.0 were
included in the study. RNA samples have been validated
as DNA-free by a no-reverse transcription assay for
Eukaryotic 18S rRNA gene (VIC-labeled TaqMan GeneBMC Cancer 2009, 9:441 http://www.biomedcentral.com/1471-2407/9/441
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Expression assay, Applied Biosystems, Foster City, CA).
RNA was amplified and reverse transcribed by WT-Ova-
tion™ RNA Amplification System kit (NuGEN Technolo-
gies, San Carlos, CA), and UCR transcripts were quantified
by Transcribed Ultra Conserved Regions real-time PCR
assays (PrimerDesign Ltd, Hants, UK) using SYBR® green
detection chemistry. Reactions were setup in 96-white-
well Twin.tec®  real-time plates (Eppendorf, Hamburg,
Germany) by EpMotion 5070 Liquid Handling Worksta-
tion (Eppendorf) and performed in duplicate on
RealPlex4 system (Eppendorf). Specificity of qPCR reac-
tions has been assessed by melting curve analysis. Accord-
ing to the Minimum Information for Publication of
Quantitative Real-Time PCR Experiments (MIQE)
[14,15], raw qPCR data and a checklist including technical
details are submitted as Supplemental data (see addi-
tional file 2: Raw Cq data; additional file 3: MIQE check-
list). The relative amount of each T-UCR to 18S rRNA was
determined using the equation 2-dCq, where dCq = (CqT-
UCR - Cq18S rRNA), as previously described [10].
Statistical analyses
Student's t-test was used to compare mean T-UCR expres-
sion levels between long- and short-surviving individuals
after logarithmic transformation of original measures. All
significance tests were two tailed. To identify those values
providing the best separation between long- and short-
survivors, T-UCR expression values were dichotomized
according to Receiver Operating Characteristic (ROC)
curves [16]. The threshold values identified with this pro-
cedure were used in subsequent survival analyses. Overall
survival (OS) was defined as the time elapsed from diag-
nosis to cancer-related death or to the date of the last fol-
low-up if the patient survived. Patients who survived were
censored at the last date they were reported to be alive.
Event free survival (EFS) was calculated from diagnosis to
the date of tumor progression or relapse or to the date of
the last follow-up if no event occurred. Survival curves
were computed according to the Kaplan-Meier method.
The Cox proportional-hazards regression model was used
to study in a multivariate setting the effect of MYCN status
(amplified, not amplified) as potential confounder. A
backward selection approach was used and only variables
with P < 0.05 were retained in the model. The MedCalc®
software (Mariakerke, Belgium) was used for statistical
analyses.
Oligonucleotide array CGH
Array CGH was performed on frozen tumors as previously
described [17] using 44K microarrays (Agilent Technolo-
gies). Array CGH data have been deposited in Gene
Expression Omnibus (GEO, http://
www.ncbi.nlm.nih.gov/geo/) and they are accessible
through GEO Series accession number GSE14109.
microRNA expression profiling
We performed microRNA expression profiling starting
from 100 ng of total RNA and following the microRNA
Microarray System protocol v.1.5 (Agilent Technologies).
In dephosphorylation and ligation steps, 17 Units of Calf
Intestine Alkaline Phosphatase (Takara Bio Inc., Shiga,
Japan) and 20 Units of T4 RNA ligase (Takara Bio Inc.)
have been used, respectively. Each sample was hybridized
on Human microRNA Microarray v.2 (Agilent Technolo-
gies) containing probes for 723 human microRNAs. Slides
were scanned by Agilent G2565BA scanner and images
were processed by Feature Extraction software v.9.5.3.1
(Agilent Technologies). Tab-delimited text file were ana-
lyzed in R v.2.7.2 software environment http://www.r-
project.org using the limma package v.2.14.16 of Biocon-
ductor http://www.bioconductor.org. Only spots with sig-
nal minus background flagged as positive and significant
were used in the following analysis as 'detected' spot.
Probes with less than 50% of detected spots across all
arrays, and arrays with a number of detected spots smaller
than 50% of all spots on the array were removed. Back-
ground corrected intensities of replicated spots on each
array were averaged. Data were then log2-transformed
and normalized for between-array comparison using
quantile normalization [18]. Differential expression anal-
ysis between "long-survivors" and "short-survivors" cate-
gory was carried out using Student's t-test (unpaired, two-
tailed, unequal variance). MicroRNAs with P-values <
0.05 were selected for further analysis. Given the explora-
tive nature of this study, no correction for multiple testing
was applied in the screening procedure aimed at selecting
multiple sets of microRNAs for subsequent hierarchical
clustering analyses. The agglomerative hierarchical clus-
ters, used to detect similarity relationships in microRNA
log2-transformed expressions, were computed by the
Euclidean distance between single vectors and the Ward
method [19]. Microarray data have been deposited in
GEO (Series accession number GSE16444).
Functionally prediction of T-UCR signature
T-UCR::microRNA sequence comparison was performed
by using the Basic Local Alignment Search Tool available
in the UCbase & miRfunc database http://micro
rna.osu.edu/UCbase4/[20]. Putative targets of microRNAs
were determined by the miRBase Targets v.5 http://micro
rna.sanger.ac.uk/targets/v5/ prediction algorithm.
Results and Discussion
T-UCR expression profiling of NB tumors
We investigated the expression of 481 T-UCRs by RT-
qPCR in two independent study groups of high-risk NB
patients. Overall, 34 NBs were investigated, including 17
tumors of patients who died of disease and 17 samples of
long-survivors. About 96% of T-UCRs were expressed in
NB samples at variable levels, with the exception of 15BMC Cancer 2009, 9:441 http://www.biomedcentral.com/1471-2407/9/441
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transcripts (uc.82, uc.105, uc.160, uc.204, uc.213, uc.284,
uc.299, uc.314, uc.327, uc.344, uc.347, uc.357, uc.363,
uc.398, uc.407) that were undetectable in all samples. Six
T-UCRs (uc.88, uc.95, uc.157, uc.162, uc.361, uc.394)
showed a Cq mean value above 35 and were therefore
considered as not expressed. The majority of T-UCRs
found in NB samples are nonexonic (53%), whereas
exonic and possibly exonic T-UCRs are transcribed at a
lower frequency (23.3% and 23.6%, respectively).
T-UCR signature of NBs
T-UCR transcription levels were initially quantified in a
set of 20 metastatic NBs of 8 short- and 12 long-survivors.
Fifty-four of the 460 detectable T-UCRs (11.7%) showed
a differential expression between the two groups (0.0004
<P < 0.0491) (see additional file 4: Table S2; additional
file 5: Figure S1). The predictive value of the 54 differen-
tially expressed on survival was analyzed in univariate
model utilizing the thresholds defined by the ROC curves
(see additional file 4: Table S2; additional file 6: Figure
S2). The Kaplan-Meier curves showed that T-UCR expres-
sion levels above the cut-off value were significantly asso-
ciated with a more favorable outcome in all 54 T-UCR for
OS (0.0001 <P < 0.0369), and only in 48 T-UCRs for EFS
(0.0001 <P  < 0.0491) (see additional file 4: Table S2;
additional file 7: Figure S3).
Then, the T-UCR threshold risk-prediction model was
tested in an independent cohort of 14 advanced stage NBs
of 9 short- and 5 long-survivors. Kaplan-Meier survival
analysis confirmed the significant association between
higher expression level and better outcome for 28 T-UCRs
(OS: 0.0007 <P < 0.0399, EFS: 0.0001 <P < 0.0399) (see
additional file 4: Table S2; additional file 8: Figure S4).
Next we wondered whether accuracy in survival predic-
tion could be improved by a combination of T-UCRs. In
this respect, the significant 28 T-UCRs were categorized as
up- or down-expressed in each NB sample according to
their respective cut-off values identified by ROC curves.
ROC and Kaplan-Meier survival analyses (Figure 1)
showed that at least 15 up-regulated T-UCRs are needed to
discriminate (P < 0.0001) long- from short-survivors at
the highest sensitivity (94.12%) and specificity (94.12%).
MYCN gene status was tested by Cox regression analysis
and it was removed during the backward selection, show-
ing that the multi-T-UCR expression signature is a MYCN-
independent predictor for OS and EFS in our cohort.
These findings endorse the identification of a novel candi-
date prognostic molecular signature based on the expres-
sion profile of the T-UCRs in high-risk NB patients.
T-UCR signature and genomic regions involved in NB
On the basis of tumor genomic DNA availability, 29
(from 14 short- and 15 long-survivors) out of the 34 NBs
were analyzed by array CGH (see additional file 1: Table
S1; additional file 9: Figure S5). Tumors from the group of
long-survivors showed 55 numerical (average 3.7 per sub-
ject) and 78 structural (average 5.2 per subject) chromo-
somal aberrations, mostly represented by 17q gain (60%)
and 11q loss (40%). All tumors of short-survivors had at
least one structural alteration (average 8.5 per subject).
The most frequent changes were 17q gain (100%), 1p loss
(57%), 2p gain (57%), 11q loss (43%), 1q gain (43%),
and 3p loss (29%). Our results confirm that severe clinical
courses are characterized by DNA changes at chromo-
somes 1, 2, 3, 7, 11, and 17 [5,6].
In order to investigate T-UCR alterations at genomic level,
we associated the location of the 28 T-UCRs with the DNA
imbalances identified in our cohort of samples. Fisher's
test disclosed a significant P-value for UCRs mapping at
3q13.31 (P  = 0.04), demonstrating that such UCRs
(namely, uc.121 and uc.122) are more specifically associ-
ated with the corresponding genome location than
expected by chance alone. According to this observation,
one unfavorable NB (#1506) shows 3q11.2-q29 loss,
whereas two tumors of long-survivors (#1889 and #2056)
harbor 3q12.2-qter and 3q13.2-q23 gain, respectively. In
this respect, we did not identify any significant T-UCR-
enrichment within the more frequently observed regions
of imbalance (i.e. 1p, 11q, 3p, 17q). In conclusion we
hypothesize that the deregulation of T-UCR expression is
not consistently associated with alterations at DNA level
in the pathogenesis and progression of high-risk NB.
Prediction of functional characterization of NB-associated 
T-UCRs
The presence of a positive correlation between expression
levels of exonic UCRs and host genes would suggest
changes in primary transcription rates. It is noteworthy
that five UCRs (uc.322, uc.323, uc.421, uc.423, and
uc.452) up-regulated in long-survivors are located within
three genes (SOX6, ZNF521, TSHZ3) that we found signif-
icantly (at a false discovery rate of 0.01) over-expressed in
long-surviving subjects of an unrelated cohort of 76 high-
risk NBs (personal microarray data, manuscript in prepa-
ration). According to these results, we speculate a positive
enhancer activity on mRNA transcription for some T-
UCRs in NB, in agreement with previous observations
[21,22].
In order to investigate the post-transcriptional regulation
of T-UCRs, we performed a genome-wide microRNA
expression analysis in 32 out of 34 samples investigated
for T-UCR levels. The expression dataset, after filtering,
condensing by replicates average and control spots
removal, contained 319 microRNAs and 31 eligible sam-
ples. Thirteen of the 319 (4.1%) microRNAs showed dif-
ferential expression between the two categories of tumorsBMC Cancer 2009, 9:441 http://www.biomedcentral.com/1471-2407/9/441
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(Figure 2; additional file 10: Figure S6). Interestingly, ALK
tyrosine kinase receptor precursor mRNA is a putative tar-
get of hsa-miR-376c that is up-regulated in tumors of
long-survivors. Although the targeting of the ALK  3'-
untranslated region by this microRNA remains to be
experimentally validated, if true, this would suggest the
importance for hsa-miR-376c to be induced in order to
negate the effects of ALK amplification in advanced NBs
[23].
Intriguingly, 4 microRNAs down-regulated in tumors of
long-survivors (hsa-miR-383, hsa-miR-548d-5p, hsa-miR-
939, hsa-miR-877*) target 3 genes implicated in neuronal
differentiation (CHD5,  FYN  and  NTRK1), that were
recently reported to be over-expressed in low-risk tumors
[7].
Since Calin et al. [10] demonstrated a negative regulation
of T-UCRs by direct interaction with microRNAs, we argue
that down-expression of the T-UCR signature in short-sur-
vivors may be due to the up-regulation of their own puta-
tive complementary microRNAs. Intriguingly, microRNA
expression data confirmed our hypothesis: 5 out of the 13
microRNAs from the signature display their expression
(A) ROC curve Figure 1
(A) ROC curve. Sensitivity and specificity in predicting survival based on different numbers of T-UCRs whose expression lev-
els are above the thresholds defined by each respective ROC curve. The point marked with the red dot represents the highest 
average of sensitivity and specificity at the cut-off value of 15 (AUC = 0.988, Z statistic = 25.078, P = 0.0001). Kaplan-Meier 
analysis for (B) overall and (C) event-free survival of all 34 NBs. Comparison of survival probabilities of patients with 
≥15 or <15 up-regulated T-UCRs. In each graph are reported the number of patients in predicted subgroups and the number 
of patients with event (between brackets).
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level that are negatively correlated with expression of 9
complementary UCRs able to differentiate between the
two NB prognosis groups (Table 1). Sequence homologies
give rise to 10 possible pairs, in agreement with previous
reports on complex redundancy in regulatory mecha-
nisms between microRNAs and T-UCRs [10].
Moreover, we speculate that a further plausible explana-
tion for the directionality of expression of T-UCRs in long-
versus short-term survivors may be due to the contribu-
tion of an epigenetic regulation of T-UCR expression. This
is supported by the fact that a CpG island methylator phe-
notype is present specifically in neuroblastoma with poor
prognosis [24,25], and that epigenetic mechanisms not
only regulate coding genes but also non-coding RNAs,
such as miRNAs [26]. According to these information, we
retrieved the promoter sequences of T-UCR-host genes
from DataBase of Transcriptional Start Sites (DBTSS,
release 7.0, http://dbtss.hgc.jp/), where each promoter
sequence contains 1 kb upstream sequence and 200 bp
sequence downstream from each transcription start site
described. Then, we used the criteria and algorithm
searcher at http://www.uscnorris.com/cpgislands2/
cpg.aspx[27] to obtain the CpG-island information. We
found that 29 out the 37 T-UCRs of the signature (78%)
mapping within coding genes are associated with CpG
islands in the promoter region of their own host genes
(see additional file 11: Table S3). Therefore, like CpG
island hypermethylation-mediated silencing of miRNAs
with tumor suppressor features contribute to human can-
cer [28], we can argue that a global DNA hypermethyla-
tion events in unfavorable neuroblastomas may affect
also T-UCR-host genes, and thus silence T-UCRs with a
potential oncogenic role in metastatic NB tumors. Experi-
mental validations will be performed in order to investi-
gate the role of methylation in the regulation of T-UCR
expression.
Conclusions
Our findings strongly suggest that a deregulation of the
microRNA/T-UCR network may play an important role in
NB. Functional studies are mandatory to clarify coding
and noncoding RNA interactions in the pathogenesis of
this tumor, and could therefore identify potential thera-
peutic targets.
The potential to use this information as the first T-UCR
prognostic signature for high-risk neuroblastoma patients
Hierarchically clustered heat map of differentially expressed microRNAs (n = 13) between the two tumors conditions Figure 2
Hierarchically clustered heat map of differentially expressed microRNAs (n = 13) between the two tumors 
conditions. Non-detected signals are indicated in white. On top bar, short-survivors tumors (yellow) and long-survivor 
tumors (blue) are shown.
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must be tested in a larger, independent set of samples.
Since immediate advantages of the qPCR strategy for T-
UCR signature evaluation are speed, cost-effectiveness,
minimal required amounts of tumor RNA, and applicabil-
ity as routine test, this pilot study should put the basis for
future analyses in order to investigate i.e., whether the T-
UCR signature described here is a sensitive and specific
genomic feature also in low- and intermediate-risk
tumors.
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Figure S1. Box-and-Whisker plots of the comparison among values of T-
UCR expression by qPCR (normalized to 18S rRNA, and after logarith-
mic transformation of original measures) between long- and short-survi-
vors. Each box represents the values from the 25th to 75th percentile, the 
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Table 1: T-UCRs whose expression inversely correlates with complementary microRNAs differentially expressed in NB patients.
T-
UCR
T-UCR expression in long- versus short-
survivors
Complementary mature 
microRNA
microRNA expression in long- versus 
short-survivors
uc.209 up-regulated hsa-miR-877* down-regulated
uc.271 up-regulated hsa-miR-383 down-regulated
uc.312 up-regulated hsa-miR-877*
hsa-miR-548d-5p
down-regulated
uc.330 up-regulated hsa-miR-548d-5p down-regulated
uc.371 up-regulated hsa-miR-877* down-regulated
uc.411 up-regulated hsa-miR-33b* down-regulated
uc.421 up-regulated hsa-miR-877* down-regulated
uc.435 up-regulated hsa-miR-939 down-regulated
uc.452 up-regulated hsa-miR-383 down-regulatedBMC Cancer 2009, 9:441 http://www.biomedcentral.com/1471-2407/9/441
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